An innovative drug achieves unprecedented results in treating blood cancer

Pharmaceutical company Regeneron announced that its experimental tumor-targeted therapy has delivered promising results, successfully eliminating the disease in several blood cancer patients who had never undergone any prior treatment.

The clinical study included 22 patients and evaluated the efficacy and safety of the new drug, odronextamab, when used in combination with chemotherapy in individuals diagnosed with diffuse large B-cell lymphoma (DLBCL).

Odronextamab is based on bispecific antibody technology, which links cancer cells to immune cells, allowing the immune system to better target and destroy malignant cells.

According to the company, patients who received a 160 mg dose of the treatment showed a complete response rate of 100%, a strong indicator of its potential effectiveness.

Diffuse large B-cell lymphoma is one of the most common and rapidly progressing blood cancers. It affects the lymphatic system—responsible for supporting immunity—and arises from an abnormal transformation of B cells, a type of white blood cell essential for defending the body.